

SPARC/Sec/SE/2020-21/044

23rd February 2021

To

National Stock Exchange of India Ltd.

Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Limited

P J Towers,
Dalal street,
Mumbai - 400001

Ref: Scrip Code: NSE: SPARC; BSE: 532872

Sub: *Update on TACLANTIS™ (Paclitaxel Injection Concentrate for Suspension) NDA*

Dear Sir/Madam,

Pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we inform you that Office of New Drugs (OND) of the U.S. Food and Drug Administration (FDA) has denied the Company's appeal of the Complete Response Letter in relation to the New Drug Application (NDA) for Taclantis™.

In its Appeal Denied letter, the OND requested the conduct of a new Phase 3 study in metastatic breast cancer patients to support any potential resubmission of the Taclantis™ NDA. The Company will review FDA's response and decide on appropriate next steps soon.

Kindly take the same on record.

Yours faithfully,

For **Sun Pharma Advanced Research Company Limited**

A handwritten signature in black ink, appearing to read "Debashis Dey", with a horizontal line extending to the right.

Debashis Dey
Company Secretary